SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 124 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $917,548 | -37.5% | 63,192 | -9.9% | 0.00% | -50.0% |
| Q2 2023 | $1,467,905 | +0.0% | 70,134 | +0.9% | 0.00% | 0.0% |
| Q1 2023 | $1,467,544 | -15.1% | 69,486 | +2.3% | 0.00% | -33.3% |
| Q4 2022 | $1,728,259 | +15.8% | 67,908 | +9.3% | 0.00% | 0.0% |
| Q3 2022 | $1,493,000 | +28.4% | 62,140 | +2.8% | 0.00% | +50.0% |
| Q2 2022 | $1,163,000 | +21.7% | 60,462 | +9.9% | 0.00% | +100.0% |
| Q1 2022 | $956,000 | -23.8% | 54,994 | -4.1% | 0.00% | 0.0% |
| Q4 2021 | $1,255,000 | +17.6% | 57,318 | +2.6% | 0.00% | 0.0% |
| Q3 2021 | $1,067,000 | +0.2% | 55,847 | -10.0% | 0.00% | 0.0% |
| Q2 2021 | $1,065,000 | +1.5% | 62,028 | +32.2% | 0.00% | 0.0% |
| Q1 2021 | $1,049,000 | +15.9% | 46,910 | +15.3% | 0.00% | 0.0% |
| Q4 2020 | $905,000 | +50.8% | 40,671 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $600,000 | -0.3% | 40,671 | +0.1% | 0.00% | 0.0% |
| Q2 2020 | $602,000 | +61.4% | 40,614 | +19.4% | 0.00% | 0.0% |
| Q1 2020 | $373,000 | +38.1% | 34,027 | +10.8% | 0.00% | – |
| Q4 2019 | $270,000 | +16.9% | 30,704 | -0.8% | 0.00% | – |
| Q3 2019 | $231,000 | -19.8% | 30,950 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $288,000 | +142.0% | 30,950 | +36.4% | 0.00% | – |
| Q1 2019 | $119,000 | +17.8% | 22,688 | 0.0% | 0.00% | – |
| Q4 2018 | $101,000 | -44.8% | 22,688 | 0.0% | 0.00% | – |
| Q3 2018 | $183,000 | +15.1% | 22,688 | 0.0% | 0.00% | – |
| Q2 2018 | $159,000 | -38.6% | 22,688 | +24.7% | 0.00% | -100.0% |
| Q1 2018 | $259,000 | +58.9% | 18,197 | -2.0% | 0.00% | – |
| Q4 2017 | $163,000 | -19.7% | 18,561 | +6.8% | 0.00% | – |
| Q3 2017 | $203,000 | -6.9% | 17,387 | +11.5% | 0.00% | – |
| Q2 2017 | $218,000 | +63.9% | 15,587 | +60.9% | 0.00% | – |
| Q1 2017 | $133,000 | +90.0% | 9,687 | -1.0% | 0.00% | – |
| Q4 2016 | $70,000 | -52.7% | 9,787 | 0.0% | 0.00% | – |
| Q3 2016 | $148,000 | +52.6% | 9,787 | -1.0% | 0.00% | – |
| Q2 2016 | $97,000 | – | 9,887 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |